MF1.F CANBRIDGE PHARM.DL-00001

Healthcare Biotechnology Frankfurt Exchange
0.1750 EUR
Close of Nov 12, 2026
0.1410 0.3060
Market cap
EUR 105M
P/E
-
P/B
0.92x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is MF1.F undervalued?

Graham number

The Graham number of CANBRIDGE PHARM.DL-00001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CANBRIDGE PHARM.DL-00001 fundamental analysis

No fundamental analysis for CANBRIDGE PHARM.DL-00001 yet.

CANBRIDGE PHARM.DL-00001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CANBRIDGE PHARM.DL-00001

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It al…

Full company profile